Liquidia Corporation to Report Full Year 2023 Financial Results on Wednesday, March 13, 2024
March 06, 2024 06:30 ET
|
Liquidia Corporation
MORRISVILLE, N.C., March 06, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its full year 2023 financial results on Wednesday, March 13, 2024. The...
Liquidia Corporation Announces Poster Presentation at the Pulmonary Vascular Research Institute 2024 Annual Congress
January 30, 2024 06:30 ET
|
Liquidia Corporation
MORRISVILLE, N.C., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) today announced that the Company will present data from the L606 clinical program...
Liquidia Corporation Provides Update on New Drug Application for YUTREPIA™ (treprostinil) inhalation powder
January 25, 2024 06:00 ET
|
Liquidia Corporation
MORRISVILLE, N.C., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (the Company) (NASDAQ: LQDA) announced today that the U.S. Food and Drug Administration (FDA) provided an update on its...
Liquidia Corporation Announces Updates to Operations Leadership
January 19, 2024 06:30 ET
|
Liquidia Corporation
MORRISVILLE, N.C., Jan. 19, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced today updates and promotions to its operations leadership in advance of the...
Liquidia Corporation Files Response to United Therapeutics Lawsuit and Files Counterclaims
January 08, 2024 08:22 ET
|
Liquidia Corporation
Seeks dismissal of all claims related to ‘793 patent based on prior findings of invalidity which have been affirmed by the Federal CircuitRequests declaration that ‘327 patent is not infringed, is...
Liquidia Provides Update on Clinical Pipeline Targeting PAH and PH-ILD
January 05, 2024 06:45 ET
|
Liquidia Corporation
Enrolled first PH-ILD patient in the open-label ASCENT study of YUTREPIAConfirmed with FDA that a single pivotal efficacy trial with L606 will support PAH and PH-ILD indications MORRISVILLE, N.C.,...
Liquidia Corporation Announces $100 Million in New Financings
January 04, 2024 09:10 ET
|
Liquidia Corporation
Agreed to $75.0 million sale of common stock to fund affiliated with Patient Square Capital in a private placementAdditional advance of $25.0 million from HealthCare Royalty under current financing...
Liquidia Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024 06:45 ET
|
Liquidia Corporation
MORRISVILLE, N.C., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced today that Dr. Roger Jeffs, Chief Executive Officer, will present at the...
U.S. Federal Circuit Affirms Earlier PTAB Decision to Invalidate All Claims of United Therapeutics Patent No. 10,716,793 (‘793 Patent)
December 20, 2023 16:56 ET
|
Liquidia Corporation
Liquidia will pursue final FDA approval for YUTREPIA™ (treprostinil) inhalationLiquidia will immediately request that District Court set aside injunction tied to ‘793 patent MORRISVILLE, N.C., Dec. ...
Liquidia Announces Pricing of Public Offering of Common Stock
December 12, 2023 07:13 ET
|
Liquidia Corporation
MORRISVILLE, N.C., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it has priced an underwritten public offering of 3,491,620 shares of common stock at a...